P.R. Modi, G.V. Patel, D.J. Daslaniya, U.L. Patel, B.V. Bhimani
P.R. Modi*, G.V. Patel, D.J. Daslaniya, U.L. Patel, B.V. Bhimani
Arihant School of Pharmacy and Bio- Research Institute, Uvarsad Cross Road, Adalaj, Gandhinagar 382421, Gujarat, India.
Volume - 6,
Issue - 4,
Year - 2013
Many therapeutic drugs are difficult to reach the central nervous system (CNS) from the systemic blood circulation because the blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSFB) form a very effective barrier which prevents most molecules from passing through it. There is the unique relationship between nasal cavity and cranial cavity tissues makes intranasal delivery to the brain feasible. An intranasal delivery provides some drugs with short channels to bypass the blood-brain barrier (BBB), especially for those with fairly low brain concentrations after a routine delivery, thus greatly enhancing the therapeutic effect on brain diseases. The nasal mucosa is nearby the brain, cerebrospinal fluid (CSF) and the drug concentrations can exceed plasma concentrations. Intranasal delivery provides a noninvasive method of bypassing the BBB to rapidly deliver therapeutic agents to the brain, spinal cord, lymphatics and to the vessel walls of the cerebrovasculature for treating CNS disorders.
Cite this article:
P.R. Modi, G.V. Patel, D.J. Daslaniya, U.L. Patel, B.V. Bhimani. Nose to Brain Drug Delivery System: A Review. Research J. Pharm. and Tech. 6(4): April 2013; Page 345-350.